Read on Twitter
Syngene concall was held today at 3:00 pm
Here are the key highlights
Here are the key highlights
Business Updates:
⢠Syngene has extended strategic collaboration with Bristol Myers Squibb for next 10 years
⢠Engaging with clients for showcase of Mangalore facility. Completed qualification process at facility.
⢠Expanded Hydrebad facility
⢠Implemented technology in plant
⢠Syngene has extended strategic collaboration with Bristol Myers Squibb for next 10 years
⢠Engaging with clients for showcase of Mangalore facility. Completed qualification process at facility.
⢠Expanded Hydrebad facility
⢠Implemented technology in plant
⢠Restarting the manufacturing of Remdivisr this month.
⢠Added 40 new clients taking the number of client count to 40.
⢠Company has extended collaboration with BMS for BBRC.
⢠BMS center now has more than 600 scientist.
⢠Current employees 5000, and was 4900 last year.
⢠Added 40 new clients taking the number of client count to 40.
⢠Company has extended collaboration with BMS for BBRC.
⢠BMS center now has more than 600 scientist.
⢠Current employees 5000, and was 4900 last year.
Capex:
⢠65Million$, of which guidelines was 100Mil, due to covid. This will be shifted utilized this year.
⢠Expanded facility in Biologics Plant.
Guidelines of growth.
⢠PAT growth to be single digit and revenue growth expected to be 2 digit.
⢠65Million$, of which guidelines was 100Mil, due to covid. This will be shifted utilized this year.
⢠Expanded facility in Biologics Plant.
Guidelines of growth.
⢠PAT growth to be single digit and revenue growth expected to be 2 digit.
EBITDA Margins:
⢠Guidelines is for next year around 30%.
⢠With global pay-group, 30% margin is sustainable over longer period.
⢠Guidelines is for next year around 30%.
⢠With global pay-group, 30% margin is sustainable over longer period.
Key learning:
⢠Go digital. 2020 showed the importance of digital channel.
Remdesivir:
⢠Out of 7 company who are having licence in India, Syngene has the smallest part. It is more sort of the CSR business, hence not much strong guidelines of revenue.
⢠Go digital. 2020 showed the importance of digital channel.
Remdesivir:
⢠Out of 7 company who are having licence in India, Syngene has the smallest part. It is more sort of the CSR business, hence not much strong guidelines of revenue.
Constant Current Term game:
⢠Dollar term growth (only sales) is around 12%.
Customer Behaviors:
⢠From past few decades there have been changes in operational work (shifting to different models) in R&D in pharma.
⢠Dollar term growth (only sales) is around 12%.
Customer Behaviors:
⢠From past few decades there have been changes in operational work (shifting to different models) in R&D in pharma.
Recruiting in India:
⢠India has fantastic talent which many Phd values.
Revenue from Non Pharma:
⢠Pharma is still the highest revenue share.
⢠Non Pharma business is expanding currently and company expects more growth to come from Non Pharma. (Around 10%)
⢠India has fantastic talent which many Phd values.
Revenue from Non Pharma:
⢠Pharma is still the highest revenue share.
⢠Non Pharma business is expanding currently and company expects more growth to come from Non Pharma. (Around 10%)
Order Book of API:
⢠Much of the order book grew over next 2 years. Now much of the focus remains on growing the client base.
CFO:
⢠For every project, company will not invest if return is less than CoC.
⢠Much of the order book grew over next 2 years. Now much of the focus remains on growing the client base.
CFO:
⢠For every project, company will not invest if return is less than CoC.
5 year vision:
⢠Syngene has now integrated the value chain.
⢠All these Discovery Research, Integrated Discovery, Finding new molecules, Clinical Trials, bringing new molecules, manufacturing is expected to grow well.
⢠Syngene has now integrated the value chain.
⢠All these Discovery Research, Integrated Discovery, Finding new molecules, Clinical Trials, bringing new molecules, manufacturing is expected to grow well.
For more discussion on Equity analysis
Subscribe to our YouTube channel
Link
: https://www.youtube.com/channel/UCDmd6AfWU8vLKv7hjBBqsGA
Subscribe to our YouTube channel
Link
: https://www.youtube.com/channel/UCDmd6AfWU8vLKv7hjBBqsGA
